Hengrui Pharma(SH:600276) Cai Jing Wang·2025-11-26 05:38Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors, with no similar drugs approved in the market currently [1] Group 1 - HRS-8364 tablets are a self-developed innovative anti-tumor drug by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - The total R&D investment for the HRS-8364 project has reached approximately 21.65 million yuan [1] Group 2 - The approval for clinical trials is a significant step, but the drug must still undergo clinical trials and regulatory reviews before it can be manufactured and marketed [1] - The drug development process is lengthy and involves uncertainties, which necessitates cautious decision-making by investors [1]